James Kihara Sells 1,790 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,790 shares of the business's stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.87, for a total transaction of $31,987.30. Following the sale, the insider now owns 13,100 shares of the company's stock, valued at $234,097. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

James Kihara also recently made the following trade(s):

• On Monday, February 26th, James Kihara sold 474 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $24.67, for a total transaction of $11,693.58.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD traded up $0.35 during midday trading on Tuesday, hitting $18.15. The stock had a trading volume of 1,371,810 shares, compared to its average volume of 1,823,083. ACADIA Pharmaceuticals Inc. has a 1 year low of $17.56 and a 1 year high of $33.99. The firm has a market cap of $2.99 billion, a PE ratio of -47.76 and a beta of 0.37. The stock's 50 day moving average is $22.20 and its 200 day moving average is $24.05.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The firm had revenue of $231.04 million during the quarter, compared to analysts' expectations of $223.79 million. During the same period in the prior year, the company posted ($0.26) EPS. The company's revenue was up 69.3% compared to the same quarter last year. As a group, equities research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 4.2% in the third quarter. Vanguard Group Inc. now owns 12,925,641 shares of the biopharmaceutical company's stock worth $211,463,000 after purchasing an additional 525,048 shares during the last quarter. RTW Investments LP grew its holdings in shares of ACADIA Pharmaceuticals by 18.3% in the third quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company's stock worth $241,255,000 after purchasing an additional 1,793,288 shares during the last quarter. BlackRock Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 1.7% in the second quarter. BlackRock Inc. now owns 10,039,501 shares of the biopharmaceutical company's stock worth $240,446,000 after purchasing an additional 170,370 shares during the last quarter. State Street Corp grew its holdings in shares of ACADIA Pharmaceuticals by 2.8% in the third quarter. State Street Corp now owns 6,778,871 shares of the biopharmaceutical company's stock worth $110,902,000 after purchasing an additional 184,921 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of ACADIA Pharmaceuticals by 6.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,550,906 shares of the biopharmaceutical company's stock worth $85,649,000 after purchasing an additional 271,652 shares during the last quarter. Hedge funds and other institutional investors own 96.71% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ACAD shares. Oppenheimer reiterated a "market perform" rating and issued a $25.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, February 5th. Royal Bank of Canada dropped their price target on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday, February 28th. Morgan Stanley dropped their price target on shares of ACADIA Pharmaceuticals from $40.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday, March 13th. Mizuho lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $39.00 to $25.00 in a research report on Tuesday, March 12th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $36.12.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.